382 related articles for article (PubMed ID: 19822065)
1. Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis.
Haibel H; Specker C
Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S159-63. PubMed ID: 19822065
[TBL] [Abstract][Full Text] [Related]
2. Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs.
van der Horst-Bruinsma IE; Clegg DO; Dijkmans BA
Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S67-70. PubMed ID: 12463451
[TBL] [Abstract][Full Text] [Related]
3. [Disease-modifying anti-rheumatic drugs for treatment of ankylosing spondylitis].
Madsen OR; Egsmose C
Ugeskr Laeger; 2009 Aug; 171(33):2268-72. PubMed ID: 19732504
[TBL] [Abstract][Full Text] [Related]
4. Treatment of rheumatoid arthritis and ankylosing spondylitis.
Braun J; Sieper J
Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S146-7. PubMed ID: 19822062
[TBL] [Abstract][Full Text] [Related]
5. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
Goodemote P; Jamieson B; Hoffman R
J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
[No Abstract] [Full Text] [Related]
6. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.
Braun J; van der Horst-Bruinsma IE; Huang F; Burgos-Vargas R; Vlahos B; Koenig AS; Freundlich B
Arthritis Rheum; 2011 Jun; 63(6):1543-51. PubMed ID: 21630245
[TBL] [Abstract][Full Text] [Related]
7. Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials.
Steiman AJ; Pope JE; Thiessen-Philbrook H; Li L; Barnabe C; Kalache F; Kung T; Bessette L; Flanagan C; Haraoui B; Hochman J; Leclercq S; Mosher D; Thorne C; Bykerk V
Rheumatol Int; 2013 May; 33(5):1105-20. PubMed ID: 23292213
[TBL] [Abstract][Full Text] [Related]
8. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
Fantò M; Peragallo MS; Pietrosanti M; Di Rosa R; Picchianti Diamanti A; Salemi S; D'Amelio R
Intern Emerg Med; 2016 Feb; 11(1):31-40. PubMed ID: 26099279
[TBL] [Abstract][Full Text] [Related]
9. [DMARDs (disease-modifying antirheumatic drugs)].
Tanaka E; Yamanaka H
Nihon Rinsho; 2013 Jul; 71(7):1199-206. PubMed ID: 23961667
[TBL] [Abstract][Full Text] [Related]
10. Prescription rheumatology practices among Mexican specialists.
Goycochea-Robles MV; Arce-Salinas CA; Guzmán-Vázquez S; Cardiel-Ríos MH
Arch Med Res; 2007 Apr; 38(3):354-9. PubMed ID: 17350489
[TBL] [Abstract][Full Text] [Related]
11. Disease-modifying anti-rheumatic drugs improve autonomic neuropathy in arthritis: DIANA study.
Syngle A; Verma I; Krishan P; Garg N; Syngle V
Clin Rheumatol; 2015 Jul; 34(7):1233-41. PubMed ID: 24928343
[TBL] [Abstract][Full Text] [Related]
12. Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
Rossini M; Viapiana O; Orsolini G; Fracassi E; Idolazzi L; Gatti D; Adami S; Govoni M
Reumatismo; 2015 Mar; 66(4):285-303. PubMed ID: 25829189
[TBL] [Abstract][Full Text] [Related]
13. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
Lanfant-Weybel K; Lequerré T; Vittecoq O
Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
[TBL] [Abstract][Full Text] [Related]
14. A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: non-steroidal anti-inflammatory drugs.
Poddubnyy D; Song IH; Sieper J
Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S148-51. PubMed ID: 19822063
[TBL] [Abstract][Full Text] [Related]
15. Use of methotrexate in patients with ankylosing spondylitis.
Haibel H; Sieper J
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S128-31. PubMed ID: 21044446
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis.
Bodur H; Ataman S; Akbulut L; Evcik D; Kavuncu V; Kaya T; Günaydin R; Kuran B; Kotevoğlu N; Bal A; Aydoğ E; Altay Z; Uğurlu H; Kocabaş H; Olmez N; Yazgan P; Gürsoy S; Madenci E; Ozel S; Delialioğlu SU
Clin Rheumatol; 2008 Sep; 27(9):1119-25. PubMed ID: 18357499
[TBL] [Abstract][Full Text] [Related]
17. Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors.
Chan J; Gladman D
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):415-426. PubMed ID: 31171312
[TBL] [Abstract][Full Text] [Related]
18. Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia.
Donges E; Staatz CE; Benham H; Kubler P; Hollingworth SA
Clin Exp Rheumatol; 2017; 35(6):907-912. PubMed ID: 28421991
[TBL] [Abstract][Full Text] [Related]
19. [Inhibition of radiographic progression in rheumatoid arthritis by anti-rheumatic drugs (DMARDs)].
Suzuki Y; Wakabayashi T; Saito E; Suwa A
Clin Calcium; 2007 Apr; 17(4):546-52. PubMed ID: 17404484
[TBL] [Abstract][Full Text] [Related]
20. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
Ranganath VK; Furst DE
Clin Geriatr Med; 2005 Aug; 21(3):649-69, viii. PubMed ID: 15911212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
